Weekly Analysts’ Ratings Updates for DBV Technologies (DBVT)

Several brokerages have updated their recommendations and price targets on shares of DBV Technologies (NASDAQ: DBVT) in the last few weeks:

• 12/10/2024 – DBV Technologies had its “market outperform” rating reaffirmed by analysts at JMP Securities. They now have a $10.00 price target on the stock.
• 12/8/2024 – DBV Technologies is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 11/30/2024 – DBV Technologies is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 11/22/2024 – DBV Technologies is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 11/14/2024 – DBV Technologies is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 11/6/2024 – DBV Technologies is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 10/29/2024 – DBV Technologies is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 10/24/2024 – DBV Technologies had its price target raised by analysts at HC Wainwright from $25.00 to $35.00. They now have a “buy” rating on the stock.
• 10/21/2024 – DBV Technologies is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 10/13/2024 – DBV Technologies is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.

DBV Technologies Trading Up 16.7 %

Shares of NASDAQ DBVT traded up $0.55 during mid-day trading on Thursday, reaching $3.84. The company had a trading volume of 4,866,993 shares, compared to its average volume of 71,306. DBV Technologies S.A. has a 52 week low of $2.20 and a 52 week high of $10.70. The business’s 50-day moving average is $3.45 and its 200-day moving average is $4.04. The stock has a market cap of $78.98 million, a price-to-earnings ratio of -0.85 and a beta of 0.64.

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.